Search the Newsreel

ZLAB - Expanding China Healthcare And Global Pipelines Will Broaden Patient Options

Zai Lab's fair value has been adjusted slightly lower to $33.30, yet the company is broadening patient options through expanding its China healthcare presence and global pipelines. Key developments include regulatory approvals for TIVDAK in China, Orphan Drug Designation for zocilurtatug pelitecan in Europe, …

Is Zai Lab’s (ZLAB) Rising Losses for Pipeline Expansion Strengthening or Straining Its Investment Case?

Zai Lab (ZLAB) reported widening net losses and softer revenue in Q2 2026, primarily due to increased investment in pipeline expansion and commercial footprint. While recent drug approvals like TIVDAK offer future revenue potential, the key challenge for Zai Lab is whether these new …

Zai Lab (ZLAB) insider William Lis plans sale of 8,506 ADS on NASDAQ

William Lis, an insider at Zai Lab (ZLAB), has filed to sell 8,506 American Depositary Shares (ADS) valued at $212,650.00. These shares originated from restricted stock vesting on June 29, 2024. The filing also notes a previous sale of 7,040 ADS on June 22, …

What Is Drawing Fresh Attention To Zai Lab (ZLAB)?

Zai Lab (ZLAB) is gaining renewed attention following its Q2 2026 earnings report, which detailed revenues of US$106.31 million and a wider net loss, along with new product approvals in China. Despite recent share price momentum, the company's 1-year return is still down 32%, …

Q2 2026 Zai Lab Ltd Earnings Call Transcript

Zai Lab Ltd (ZLAB) is transitioning into a global biopharmaceutical company, with its lead asset, ZL-1310 (DLL3 ADC), progressing rapidly towards regulatory submission. The company reported an 11% sequential growth in net product revenue in Q2 2026, reaching $105.8 million, driven by strong demand …

Zai Lab Limited (NASDAQ:ZLAB) Just Reported And Analysts Have Been Cutting Their Estimates

Zai Lab Limited reported solid quarterly results, with revenues exceeding analyst forecasts and statutory losses being smaller than expected. However, analysts have slightly downgraded revenue estimates for 2026 and expect losses to increase, while the consensus price target remains largely unchanged. The company's projected …

Is Zai Lab’s (ZLAB) Rising Loss on Softer Revenue Reframing Its Investment-Led Growth Story?

Zai Lab Limited reported second-quarter 2026 results showing revenue of US$106.31 million versus US$109.98 million a year earlier, with net loss widening to US$50.83 million from US$40.73 million and basic loss per share increasing to US$0.50 from US$0.40. Over the first half of 2026, …

Zai Lab (ZLAB) Rebounds Following Earnings While Its Undervalued Narrative Faces A Fresh Test

Zai Lab (ZLAB) saw its stock rebound after reporting Q2 2026 earnings, with an 11.69% 1-day and 27.64% 7-day share price return, despite wider net losses. The company is currently considered 30% undervalued with a fair value estimate of $33.30, driven by anticipated product …

Zai Lab (ZLAB) Stock May Trade At A Sales Premium Despite Stronger Broader Checks

Zai Lab's stock has seen a sharp rebound but its long-term performance shows an 84.5% decline over five years. Despite regulatory progress like Orphan Drug Designation for Zocilurtatug Pelitecan, the stock appears overvalued with a P/S ratio of 5.8x compared to a tailored fair …

UBS Keeps Their Buy Rating on Zai Lab Ltd (1ZLB)

UBS has reiterated its Buy rating on Zai Lab Ltd (1ZLB), setting a price target of HK$27.00. The analyst consensus for Zai Lab Ltd is currently a Strong Buy with an average price target of €3.03, reflecting a positive outlook on the company. Zai …

Zai Lab (ZLAB) Stock Jumps As Revenue Holds But Losses Deepen

Zai Lab (ZLAB) stock rose 11.7% despite deepening losses, driven by strong Q2 revenue figures and a profitable commercial business in China. The company reported Q2 net product revenue of US$105.8 million, with total revenue reaching US$106.3 million, but a net loss of US$50.8 …

Cantor Fitzgerald Maintains Zai Lab(ZLAB.US) With Buy Rating, Maintains Target Price $37

Cantor Fitzgerald has reiterated its Buy rating on Zai Lab (ZLAB.US) and maintained its price target at $37. This indicates a continued positive outlook from the firm regarding Zai Lab's stock performance.

Zai Lab (NASDAQ:ZLAB) Issues Earnings Results, Beats Estimates By $0.18 EPS

Zai Lab Ltd (ZLAB) (Q2 2026) Earnings Call Highlights: Global Biopharma Inflection Point with U. ...

This article first appeared on GuruFocus. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Zai Lab Ltd (NASDAQ:ZLAB) has reached an inflection point, transitioning from a regional business into …

Zai Lab Limited 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ZLAB) 2026-08-06

Zai Lab (NASDAQ: ZLAB) posts Q2 2026 net loss of $50.8M

Zai Lab (NASDAQ: ZLAB) reported a net loss of $50.8 million in Q2 2026, or $0.46 per ADS, despite total revenues of $106.3 million. The company highlighted significant pipeline progress, including multiple regulatory designations for zocilurtatug pelitecan (zoci) and commercial launches of TIVDAK and …

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

For the quarter ended June 2026, Zai Lab Limited Unsponsored ADR (ZLAB) reported revenue of $106.31 million, down 3.3% over the same period last year. EPS came in at -$0.46, compared to -$0.37 in the year-ago quarter. The reported revenue compares to the Zacks …

Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Revenue $106.3M, vs. FactSet Est of $103.9M

Zai Lab Ltd 2026: Revenue $105.75M, EPS ($0.05) — 10-Q Summary

Zai Lab Ltd reported its 2026 quarterly results, showing product revenue of $105.75M and a diluted loss per share of ($0.05). This represents a decrease in revenue and an increased net loss compared to the prior year, primarily due to shifts in channel and …

Zai Lab (NASDAQ: ZLAB) expands pipeline as Q2 2026 loss reaches $50.8M

Zai Lab reported Q2 2026 total revenues of $106.3 million, a modest decrease from the prior year, leading to a net loss of $50.8 million ($0.05 per ordinary share) due to increased R&D spending. Despite a decline in ZEJULA and VYVGART revenues, the company …

Does New US Orphan Drug Status For Zoci Reshape The Bull Case For Zai Lab (ZLAB)?

Zai Lab recently received U.S. FDA Orphan Drug Designation for Zoci, its DLL3-targeting antibody-drug conjugate, for treating neuroendocrine carcinomas. This designation, following a similar one in Europe, highlights Zoci's potential as a first-in-class therapy for difficult cancers. While it strengthens Zai Lab's long-term pipeline, …

ZLAB|Zai Lab Ltd|Price:18.270|Chg%:+0.060

This article provides a comprehensive stock analysis of Zai Lab Ltd (ZLAB) through TradingKey's scoring system, highlighting its strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The analysis notes significant institutional ownership and a recent "Buy" rating from multiple analysts …

Zai Lab Ltd (ZLAB) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of Zai Lab Ltd (ZLAB), noting its current valuation score of 9.77, ranking 2nd in the Pharmaceuticals industry. It highlights the company's P/E ratio of -11.31, which is significantly below its recent high and above its recent low. …

Zai Lab Ltd (ZLAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Zai Lab Ltd (ZLAB). It details the company's price momentum score, current support and resistance levels, and a comprehensive breakdown of technical indicators like MACD, RSI, and Moving Averages. The analysis suggests a Neutral signal based on …

Zai Lab (ZLAB) to Post Quarterly Earnings on Thursday

ZLAB|Zai Lab Ltd|Price:19.220|Chg%:-0.460

This article provides an overview of Zai Lab Ltd (ZLAB), a biopharmaceutical holding company focused on addressing unmet medical needs in various disease areas. It includes current stock performance, key company information such as its IPO date and CEO, and a list of its …

Zai Lab (ZLAB) Faces A 42% Undervalued View, Is The Market Too Cautious?

Zai Lab (ZLAB) stock is currently viewed as 42% undervalued, trading at $19.22 against a fair value of $33.30, despite recent share price declines. This valuation is based on expectations of significant revenue growth and margin improvements from multiple high-potential product launches and pipeline …

Zai Lab Ltd (ZLAB) Q1 2026 Earnings Report - Results, Call & Slides

Zai Lab Ltd (ZLAB) reported its Q1 2026 earnings, beating EPS estimates by $0.07 with an actual EPS of -$0.46, though revenue of $99.91 million missed expectations by $8.52 million. The company highlighted strong clinical progress with Zoci and an expanding pipeline, despite short-term …

ETFs Investing in Zai Lab Ltd. Sponsored ADR Stocks

This article lists various ETFs that hold Zai Lab Ltd. Sponsored ADR stocks, providing financial details for each fund such as market value, weight, issuer, expense ratio, AUM, and price performance. It highlights how these ETFs offer accessible and diversified opportunities for investing in …

A2DX1V Forecast — Price Target — Prediction for 2027

This article provides a price target and prediction for A2DX1V (Zai Lab Ltd. Sponsored ADR) for 2027. It indicates a price target of 28.81 based on 13 analysts' 1-year forecasts, without specifying max or min estimates. The report also mentions sections for analyst ratings, …

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced it will report its second quarter 2026 financial results and provide corporate updates on August 6, 2026, before U.S. equity markets open. The announcement will be followed by a conference call and webcast at 8:00 a.m. …

Zai Lab stock steadies as cancer portfolio expands and revenue rises

Zai Lab (ZLAB) stock is stabilizing due to an expanding oncology and autoimmune portfolio, leading to double-digit revenue growth and narrowing losses. The company reported roughly $90 million in product revenue for its latest quarter, up over 20% year-on-year, and reduced its net loss …

Zai Lab (ZLAB) Rebounds Sharply, Is The Valuation Gap An Opportunity?

Zai Lab (ZLAB) has seen a sharp rebound in its share price, now trading at US$20.20, after a period of decline. The article explores whether the significant valuation gap, with a fair value estimated at $33.30, presents an opportunity for investors, driven by upcoming …